KYNB Company Profile and Key Details

NASDAQ : KYNB

Kyntra Bio

$6.71

-0.1-1.47%

Open: 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kyntra Bio, Inc. (KYNB) stock declined over -1.47%, trading at $6.71 on NASDAQ, down from the previous close of $6.81. The stock opened at $6.80, fluctuating between $6.65 and $6.88 in the recent session.

Stock Snapshot

6.81

Prev. Close

27.16M

Market Cap

6.65

Day Low

-0.48

P/E Ratio

-13.99

EPS (TTM)

N/A

Cash Flow per Share

6.8

Open

4.05M

Number of Shares

6.875

Day High

N/A

Free Float in %

N/A

Book Value

6.74K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 05, 2026	6.80	6.88	6.65	6.71	6.83K
Jun 04, 2026	6.85	6.99	6.80	6.81	3.84K
Jun 03, 2026	6.80	6.81	6.80	6.81	5.79K
Jun 01, 2026	6.91	6.98	6.80	6.90	18.73K
May 29, 2026	7.05	7.05	6.86	6.90	6.65K
May 28, 2026	7.05	7.09	7.01	7.02	7.33K
May 27, 2026	6.96	7.17	6.96	7.01	9.3K
May 26, 2026	6.99	7.07	6.85	6.85	5.96K
May 22, 2026	6.82	7.05	6.82	6.99	11.63K
May 21, 2026	6.93	6.95	6.88	6.94	5.59K
May 20, 2026	6.85	6.97	6.85	6.95	2.75K
May 19, 2026	6.78	6.90	6.78	6.80	11.01K
May 18, 2026	6.95	7.02	6.81	6.83	11.1K
May 15, 2026	6.95	7.02	6.82	6.82	9.95K
May 14, 2026	7.01	7.10	6.96	7.01	9.19K
May 13, 2026	7.08	7.14	7.00	7.00	9.53K
May 12, 2026	6.89	7.23	6.80	7.23	12.91K
May 11, 2026	6.95	7.03	6.80	6.80	15.62K
May 08, 2026	7.05	7.09	6.95	6.95	4.87K
May 07, 2026	7.07	7.20	7.07	7.10	11.87K

Contact Details

San Francisco, CA 94133

United States

https://www.kyntrabio.com 415 978 1200

About Company

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Stock Peers

ONC

-9.83-3.51%

BeOne Medicines Ltd.$270.10 HROWM

-0.02-0.08%

Harrow Health, Inc. 11.875% Senior Notes due 2027$26.03 HROWL

0.0478+0.19%

Harrow Health, Inc. 8.625% Senior Notes due 2026$25.61 LFMDP

-0.05-0.21%

LifeMD, Inc.$23.60 CGEM

-0.92-6.38%

Cullinan Therapeutics, Inc.$13.51 WBA

0.06+0.50%

Walgreens Boots Alliance, Inc.$11.98 MEDS

0.33+4.55%

TRxADE HEALTH, Inc.$7.59 POZN

-0.41-6.90%

POZEN Inc.$5.94 MSLE

-0.39-6.49%

Satellos Bioscience Inc. Common Stock$5.62 LFMD

0.02+0.41%

LifeMD, Inc.$4.89

Company Overview

Kyntra Bio, Inc. (NASDAQ:KYNB) closed at $6.71 USD, losing -$0.10 (-1.47%) from the previous close of $6.81. The stock is currently mid-range between its 52-week high and low $4.85 and $12.60. With a market capitalization of about $27.16 million, Kyntra Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 17.51 thousand shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Kyntra Bio, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Thane Wettig, the company employs approximately 225 people and listed since November 14, 2014. Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -10.25%, SMA50 -17.68%, SMA200 -21.94%). The stock’s 14-day RSI is 37.25 (weak momentum), while the ATR of 0.61 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.07% below its high and over 43.71% above its low. Average 10-day trading volume of 8.35 thousand shares is below the 3-month average of 17.69 thousand, indicating normal recent market interest.

Valuation Metrics

Kyntra Bio, Inc. trades at a P/E ratio of 0.17, slightly below the S&P 500 average, with a price-to-sales ratio of 3.64 and a price-to-book ratio of -0.62 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.27, also below market averages.

Dividend & Fair Value

Kyntra Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.61. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Kyntra Bio, Inc. generated EPS of $40.44 over the past year. Five-year average earnings growth is 11.75%. Wall Street analysts project EPS growth of -6.88% annually over the next five years. Kyntra Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 11.9%. The prior quarter beat by -7.2%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 17, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Kyntra Bio has not generated any revenue.
On valuation metrics, Kyntra Bio trades at a P/E of 0.17, P/S of 3.64 and P/B of -0.62. The current ratio is 3.61 and quick ratio is 3.48. Operationally, the company’s inventory turnover is 1.21 and cash conversion cycle is 94.43 days. Debt-to-equity is -0.44, supported by a cash flow-to-debt ratio of -1.11.

Price Forecast & Outlook

Our AI price prediction model suggests that Kyntra Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.89%, with price expected at $6.65 by June 19, 2026, within a range of $6.51 to $6.78 3-Month Outlook: Projected fall of -97.76%, reaching $0.15 by September 03, 2026, with a range of $0.09 to $0.22. 1-Year Outlook: Projected gain of 239.34%, with price at $22.77 by June 04, 2027, within a range of $22.70 to $22.83.

Key Takeaways

Kyntra Bio, Inc. (NASDAQ:KYNB) shares are flat -2.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kyntra Bio, Inc. trading at a premium to the broader market with a P/E of 0.17. Our AI forecast model points to short-term weakness (-0.89% over two weeks), a medium-term fall (-97.76% over three months), and a longer-term gain (239.34% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Kyntra Bio, Inc. (KYNB) stock price?

Kyntra Bio, Inc. (NASDAQ: KYNB) stock price is $6.71 in the last trading session. During the trading session, KYNB stock reached the peak price of $6.88 while $6.65 was the lowest point it dropped to. The percentage change in KYNB stock occurred in the recent session was -1.47% while the dollar amount for the price change in KYNB stock was - $0.10.

KYNB's industry and sector of operation?

The NASDAQ listed KYNB is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector. Kyntra Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KYNB?

No Data

How KYNB did perform over past 52-week?

KYNB's closing price is 38.35% higher than its 52-week low of $4.85 where as its distance from 52-week high of $12.60 is -46.75%.

How many employees does KYNB have?

Number of KYNB employees currently stands at 225.

Link for KYNB official website?

Official Website of KYNB is: https://www.kyntrabio.com

How do I contact KYNB?

KYNB could be contacted at phone 415 978 1200 and can also be accessed through its website. KYNB operates from 350 Bay Street, San Francisco, CA 94133, United States.

How many shares of KYNB are traded daily?

KYNB stock volume for the day was 6.74K shares. The average number of KYNB shares traded daily for last 3 months was 17.51K.

What is the market cap of KYNB currently?

The market value of KYNB currently stands at $27.16M with its latest stock price at $6.71 and 4.05M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	225
Beta	0.93
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Medical - Pharmaceuticals

KYNB Company Profile and Key Details

Kyntra Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview